<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019561</url>
  </required_header>
  <id_info>
    <org_study_id>D5671C00002</org_study_id>
    <nct_id>NCT04019561</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study with 4 treatment groups of two differing doses and matched placebos designed&#xD;
      to evaluate the safety (including hepatic safety), tolerability and pharmacodynamic effects&#xD;
      of two dose levels of MEDI0382 in obese subjects with non-alcoholic fatty liver disease&#xD;
      (NAFLD)/non-alcoholic steatohepatitis (NASH). The subjects will have biopsy-confirmed&#xD;
      NAFLD/NASH with liver fibrosis stage F1, F2 or F3. Approximately 72 subjects will be&#xD;
      randomized&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, study to evaluate the safety&#xD;
      (including hepatic safety), tolerability and pharmacodynamic effects of two dose levels of&#xD;
      MEDI0382 in obese subjects with non-alcoholic fatty liver disease (NAFLD)/non-alcoholic&#xD;
      steatohepatitis (NASH). The subjects will have biopsy-confirmed NAFLD/NASH with liver&#xD;
      fibrosis stage F1, F2 or F3. Approximately 72 subjects will be randomized across multiple&#xD;
      study sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Actual">May 6, 2021</completion_date>
  <primary_completion_date type="Actual">May 6, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety (including hepatic safety) and tolerability of MEDI0382 compared with placebo</measure>
    <time_frame>Day 1 - Day 161</time_frame>
    <description>Number and percentage of subjects with treatment emergent adverse events and serious adverse events through the end of the follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic fat</measure>
    <time_frame>Basaeline - Week 19</time_frame>
    <description>Percent change from baseline in hepatic fat fraction (HFF) at Week 19 assessed by MRI-PDFF compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic fat</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Absolute change from baseline in hepatic fat fraction (HFF) at Week 19 assessed by MRI-PDFF compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver volume</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in:&#xD;
liver fat volume assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver fat volume</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in:&#xD;
liver fat volume assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in visceral adipose tissue assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subcutaneous adipose tissue</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in subcutaneous adipose tissue assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver diffusion</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in liver diffusion assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal sagittal diameter (image based)</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in abdominal sagittal diameter (image based)assessed by MRI compared with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal transversal diameter (image based)</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in abdominal transversal diameter (image based)assessed by MRI compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating markers of hepatic inflammation</measure>
    <time_frame>Basaeline - Week 19</time_frame>
    <description>Changes from baseline to Week 19 in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of MEDI0382 on BMI</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Change and percent change from baseline to week 19 on BMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the dose response of MEDI0382 on HFF by MRI-PDFF</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Absolute change from baseline in HFF from baseline to week 19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the dose response of MEDI0382 on body weight</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Change from baseline to week 19 on body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the dose response of MEDI0382 on hepatic safety</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Measured by the incidences of treatment emergent adverse events and serious adverse events through the end of the follow up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the dose response of MEDI0382 on imaging parameters.</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Measured by the change in baseline to week 19 on:&#xD;
Liver fat volume visceral adipose tissue subcutaneous adipose tissue liver diffusion liver sagittal diameter liver transversal diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the dose response of MEDI0382 on circulating biomarkers of hepatic inflammation</measure>
    <time_frame>Baseline - Week 19</time_frame>
    <description>Measured by the change in baseline to week 19 in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile defined by presence of anti-drug antibodies (ADA)</measure>
    <time_frame>Day 1 - Day 161</time_frame>
    <description>Development of ADA and titer (if confirmed positive) during treatment and follow up</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease (NAFLD)</condition>
  <condition>Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>MEDI0382 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0382 high dose administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MEDI0382 high dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for MEDI0382 high dose administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI0382 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0382 low dose administered subcutaneoously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MEDI0382 low dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for MEDI0382 low dose administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0382 high dose</intervention_name>
    <description>MEDI0382 high dose administered subcutaneously</description>
    <arm_group_label>MEDI0382 high dose</arm_group_label>
    <other_name>Cotadutide high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MEDI0382 high dose</intervention_name>
    <description>Placebo for MEDI0382 high dose administered subcutaneously</description>
    <arm_group_label>Placebo for MEDI0382 high dose</arm_group_label>
    <other_name>Placebo high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0382 low dose</intervention_name>
    <description>MEDI0382 low dose administered subcutaneously</description>
    <arm_group_label>MEDI0382 low dose</arm_group_label>
    <other_name>Cotadutide low dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MEDI0382 low dose</intervention_name>
    <description>Placebo for MEDI0382 low dose administered subcutaneously</description>
    <arm_group_label>Placebo for MEDI0382 low dose</arm_group_label>
    <other_name>Placebo low dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent (with the exception of consent for future genetic and&#xD;
             non genetic research) prior to performing any study-specific procedures, including&#xD;
             screening evaluations.&#xD;
&#xD;
          2. Subjects aged ≥ 18 years at the time of consent.&#xD;
&#xD;
          3. Body mass index ≥ 30 kg/m2 at screening.&#xD;
&#xD;
          4. HbA1c ≤ 9.5% (inclusive) at screening if T2DM present, managed by either diet and/or a&#xD;
             stable dose of metformin, sodium-glucose co-transporter 2 (SGLT-2) inhibitors,&#xD;
             sulphonylureas or acarbose (ie, no major dose adjustments in prior 3 months to&#xD;
             screening).&#xD;
&#xD;
          5. Definitive NAFLD / NASH with NASH activity score (NAS) ≥ 4 with ≥ 1 in each component&#xD;
             (i.e. steatosis, lobular inflammation and ballooning), as diagnosed by liver biopsy&#xD;
             within 6 months of screening with liver fibrosis stage F1, F2 or F3. The number of&#xD;
             subjects with F1 will be capped at 25% in the study.&#xD;
&#xD;
          6. Evidence of hepatic steatosis or liver fat (≥ 10%) by MRI.&#xD;
&#xD;
          7. Women of childbearing potential:&#xD;
&#xD;
               1. Who are sexually active with a non-sterilized male partner must have used at&#xD;
                  least one highly effective method of contraception from screening, and must agree&#xD;
                  to continue using such precautions through to the end of the study. It is&#xD;
                  strongly recommended for the male partner of a female subject to also use male&#xD;
                  condom plus spermicide throughout this period. Cessation of contraception after&#xD;
                  this point should be discussed with a responsible physician. Periodic abstinence,&#xD;
                  the rhythm method, and the withdrawal method are not acceptable methods of&#xD;
                  contraception.&#xD;
&#xD;
               2. Must have a negative urine pregnancy test within 72 hours prior to the first dose&#xD;
                  of investigational product; and not be breastfeeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of, or any existing condition that, in the opinion of the investigator, would&#xD;
             interfere with evaluation of the investigational product, put the subject at risk,&#xD;
             influence the subject's ability to participate or affect the interpretation of the&#xD;
             results of the study.&#xD;
&#xD;
          2. Liver disease of other etiologies (eg, alcoholic steatohepatitis; drug-induced, viral,&#xD;
             or autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis;&#xD;
             hemochromatosis; alpha 1 antitrypsin deficiency; Wilson's disease) including positive&#xD;
             results for hepatitis B surface antigen (HBsAg) or hepatitis C antibody tests&#xD;
             (anti-HCV).&#xD;
&#xD;
          3. History of cirrhosis and/or hepatic decompensation, including ascites, hepatic&#xD;
             encephalopathy or variceal bleeding.&#xD;
&#xD;
          4. Prior or planned liver transplantation.&#xD;
&#xD;
          5. Alcohol consumption &gt; 21 units of alcohol per week for men and &gt; 14 units per week for&#xD;
             women on average over a two-year time frame prior to baseline biopsy.&#xD;
&#xD;
          6. Evidence of alcohol dependence as assessed by the Alcohol Use Disorder Identification&#xD;
             Test (AUDIT) questionnaire at screening&#xD;
&#xD;
          7. A history of type 1 diabetes mellitus (T1DM), a history of diabetic ketoacidosis or&#xD;
             current use of insulin-based therapies.&#xD;
&#xD;
          8. Clinically significant inflammatory bowel disease or other severe disease or surgery&#xD;
             affecting the upper GI tract (including bariatric surgery) which may affect gastric&#xD;
             emptying or could affect the interpretation of safety and tolerability data&#xD;
&#xD;
          9. Physician-diagnosed diabetic subjects with clinically significant gastroparesis (as&#xD;
             judged by the investigator) or those treated for gastroparesis within 6 months prior&#xD;
             to screening&#xD;
&#xD;
         10. History of &gt; 5 kg weight loss in the last 6 months prior to screening or recent&#xD;
             (within 3 months of screening) use of drugs approved for weight loss (eg, orlistat,&#xD;
             bupropion / naltrexone, phentermine-topiramate, phentermine, lorcaserin), as well as&#xD;
             those drugs used off-label.&#xD;
&#xD;
         11. Clinically significant cardiovascular or cerebrovascular disease within the past 3&#xD;
             months, including but not limited to, myocardial infarction, acute coronary syndrome&#xD;
             or stroke, or subjects who have undergone percutaneous coronary intervention or a&#xD;
             coronary artery bypass graft within the past 6 months or who are due to undergo these&#xD;
             procedures at the time of screening.&#xD;
&#xD;
         12. Severe congestive heart failure (New York Heart Association Class IV).&#xD;
&#xD;
         13. History of neoplastic disease within 5 years prior to screening, except for adequately&#xD;
             treated basal cell, squamous cell skin cancer, or in situ cervical cancer.&#xD;
&#xD;
         14. History of substance dependence or a positive screen for drugs of abuse, likely to&#xD;
             impact subject safety or compliance with study procedures, at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
         15. History of psychosis or bipolar disorder. History of major depressive disorder within&#xD;
             the past year with the subject being clinically unstable, or any history of suicide&#xD;
             attempt or history of suicidal ideation within the past year.&#xD;
&#xD;
         16. Recent (within 3 months of baseline biopsy) use of therapies associated with&#xD;
             development of NAFLD (eg, systemic corticosteroids, methotrexate, tamoxifen,&#xD;
             amiodarone, or long-term use of tetracyclines).&#xD;
&#xD;
         17. Recent (within 3 months of baseline biopsy) use of obeticholic acid or other therapy&#xD;
             under investigation for NASH.&#xD;
&#xD;
         18. High dose vitamin E (&gt; 400 IU) unless on a stable dose for at least 1 year prior to&#xD;
             the baseline biopsy, and not initiated after the biopsy was taken.&#xD;
&#xD;
         19. Recent (within 3 months of baseline biopsy) use of GLP-1 receptor agonist or GLP-1&#xD;
             receptor agonist containing therapies.&#xD;
&#xD;
         20. Any subject who has received another investigational product as part of a clinical&#xD;
             study within the last 30 days or 5 half-lives of the therapy (whichever is longer) at&#xD;
             the time of screening. Any prior exposure to MEDI0382 is not permitted.&#xD;
&#xD;
         21. Concurrent participation in another interventional study of any kind or repeat&#xD;
             randomization in this study.&#xD;
&#xD;
         22. Severe allergy/hypersensitivity to any of the proposed study treatments or excipients.&#xD;
&#xD;
         23. Contra-indication to MRI: such as subjects with pacemakers, metallic cardiac valves,&#xD;
             magnetic material such as surgical clips, implanted electronic infusion pumps or other&#xD;
             conditions that would preclude proximity to a strong magnetic field; subjects with&#xD;
             history of extreme claustrophobia or subject cannot fit inside the MR scanner cavity.&#xD;
&#xD;
         24. History of acute pancreatitis or current chronic pancreatitis. Subjects with serum&#xD;
             triglyceride concentrations above 1000 mg/dL (11 mmol/L) at screening, as this can&#xD;
             precipitate acute pancreatitis.&#xD;
&#xD;
         25. Abnormal laboratory values including any of the following:&#xD;
&#xD;
               1. AST or ALT &gt; 5 × ULN.&#xD;
&#xD;
               2. Impaired renal function defined as estimated glomerular filtration rate (eGFR) ≤&#xD;
                  30 mL/minute/1.73 m2 at screening (estimated according to chronic kidney disease&#xD;
                  epidemiology collaboration [CKD-EPI]).&#xD;
&#xD;
               3. Albumin &lt; 35 g/L.&#xD;
&#xD;
               4. International normalized ratio (INR) &gt; 1.3.&#xD;
&#xD;
               5. Total Bilirubin (TBL) &gt; 25 µmol/L in the absence of known Gilbert's disease.&#xD;
&#xD;
               6. Platelets &lt; 140-150,000/mm3&#xD;
&#xD;
               7. Any other clinically significant abnormalities in clinical chemistry, hematology,&#xD;
                  or urinalysis results as judged by the investigator.&#xD;
&#xD;
         26. Severely uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mm&#xD;
             Hg and/or diastolic blood pressure (DBP) ≥ 110 mm Hg on the average of 2 seated&#xD;
             measurements after being at rest for at least 10 minutes at screening or&#xD;
             randomization.&#xD;
&#xD;
         27. Basal calcitonin level &gt; 50 ng/L at screening, or history/family history of medullary&#xD;
             thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).&#xD;
&#xD;
         28. Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration &lt; 11.5&#xD;
             g/dL [115 g/L] for male subjects or &lt; 10.5 g/dL [105 g/L] for female subjects) at&#xD;
             screening, or any other condition known to interfere with interpretation of HbA1c&#xD;
             measurements&#xD;
&#xD;
         29. Any positive results for human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         30. Any AstraZeneca, MedImmune, contract research organization (CRO), or study site&#xD;
             employee, or close relatives of any of the aforementioned employees.&#xD;
&#xD;
         31. Females who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blue Ash</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Non-alcoholic steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>0382</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

